Lonafarnib is a potential inhibitor for neovascularization

Area of Science:

• Cardiovascular Research
• Molecular Biology
• Cell Biology

Background:

• Atherosclerosis involves plaque buildup and intraplaque neovascularization.
• Farnesyl transferase inhibitors show potential in preventing atherosclerosis.
• The precise mechanism of farnesyl transferase inhibitors in atherosclerosis is not fully understood.

Purpose of the Study:

• To investigate the mechanism by which lonafarnib, a farnesyl transferase inhibitor, affects neovascularization in atherosclerosis.
• To determine if lonafarnib directly impacts endothelial cells and their functions.

Main Methods:

• In vitro studies using endothelial cells to assess capillary assembly, wound closure, and proliferation.
• Analysis of centrosome reorientation and cytoskeletal protein interactions.
• Pharmacological inhibition of farnesyl transferase using lonafarnib.

Main Results:

• Lonafarnib inhibited endothelial capillary assembly and scratch wound closure in a dose-dependent manner.
• Lonafarnib did not significantly affect endothelial cell proliferation.
• Lonafarnib impaired centrosome reorientation and disrupted the interaction between farnesyl transferase and a key cytoskeletal protein.

Conclusions:

• Lonafarnib inhibits neovascularization by directly targeting endothelial cell motility.
• Farnesyl transferase inhibition impacts endothelial cell polarity and cytoskeletal dynamics.
• These findings provide mechanistic insight into the protective effects of farnesyl transferase inhibitors against atherosclerosis.